Biologic Immunomodulatory Therapies in the Vasculitic Diseases

The expanding range of biologic agents capable of modulating the immune response has opened up a new realm for therapeutic exploration in the vasculitic diseases. Partnered with increasing knowledge regarding the mechanisms of vascular inflammation, these agents have raised the question as to whether it may be possible to treat systemic vasculitis syndromes by selectively targeting pathways involved in disease pathogenesis. The action of these agents to directly modulate specific immunologic components offers the potential not only to impact disease activity but also to reduce the risk of morbidity that can result from currently available treatment options. The study of biologic therapies in the vasculitides must, however, be approached with caution because unanticipated effects on disease activity and disease-specific toxicities can occur. The only biologic agent that has currently been shown to have therapeutic efficacy in a systemic vasculitis syndrome is interferon-α in the treatment of hepatitis C-associated cryoglobulinemic vasculitis. The use of biologic agents to treat other vasculitides remains investigational. Methodical evaluation of biologic agents prior to their use in general clinical practice is essential to understand their safety and efficacy. Rigorous, standardized investigations may also provide important insights into pathogenesis of the vasculitic diseases.

Vasculitis - monoclonal - recombinant - biologic - treatment

REFERENCES

• 1 Criscione L G, St Clair E W. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.  Curr Opin Rheumatol. 2002;  14 204-211
• 2 Patel D D. B cell-ablative therapy for the treatment of autoimmune diseases.  Arthritis Rheum. 2002;  46 1984-1985
• 3 Fisher Jr C J, Agosti J M, Opal S M et al.. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.  N Engl J Med. 1996;  334 1697-1702
• 4 Robinson W H, Genovese M C, Moreland L W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?.  Arthritis Rheum. 2001;  44 1977-1983
• 5 TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study . The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.  Neurology. 1999;  53 457-465
• 6 Sicotte N L, Voskuhl R R. Onset of multiple sclerosis associated with anti-TNF therapy.  Neurology. 2001;  57 1885-1888
• 7 van Oosten B W, Barkhof F, Truyen L et al.. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.  Neurology. 1996;  47 1531-1534
• 8 Sneller M C. Granuloma formation, implications for the pathogenesis of vasculitis.  Cleve Clin J Med. 2002;  69(suppl 2) SII40-SII43
• 9 Ludviksson B R, Sneller M C, Chua K S et al.. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.  J Immunol. 1998;  160 3602-3609
• 10 Csernok E, Trabandt A, Müller A et al.. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation.  Arthritis Rheum. 1999;  42 742-750
• 11 Stone J H, Uhlfelder M L, Hellmann D B et al.. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.  Arthritis Rheum. 2001;  44 1149-1154
• 12 Lamprecht P, Voswinkel J, Lilienthal T et al.. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.  Rheumatology (Oxford). 2002;  41 1303-1307
• 13 Booth A D, Jefferson H J, Ayliffe W, Andrews P A, Jayne D R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis.  Ann Rheum Dis. 2002;  61 559
• 14 Bartolucci P, Ramanoelina J, Cohen P et al.. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.  Rheumatology (Oxford). 2002;  41 1126-1132
• 15 Russell K A, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon.  Rheum Dis Clin North Am. 2001;  27 815-832
• 16 Preston G A, Yang J J, Xiao H, Falk R J. Understanding the pathogenesis of ANCA: where are we today?.  Cleve Clin J Med. 2002;  69(suppl 2) SII51-SII54
• 17 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.  J Clin Invest. 2002;  110 955-963
• 18 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 2836-2840
• 19 Lockwood C M, Thiru S, Isaacs J D, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.  Lancet. 1993;  341 1620-1622
• 20 Lockwood C M, Thiru S, Stewart S et al.. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.  QJM. 1996;  89 903-912
• 21 Jayne D RW. CAMPATH-1H (anti-CD-52) for refractory vasculitis: retrospective Cambridge experience 1989-1999.  Cleve Clin J Med. 2002;  69(suppl 2) SII-129
• 22 Mathieson P W, Cobbold S P, Hale G et al.. Monoclonal-antibody therapy in systemic vasculitis.  N Engl J Med. 1990;  323 250-254
• 23 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa.  Am J Pathol. 1951;  27 277-301
• 24 Hellmich B, Ehlers S, Csernok E, Gross W L. Update on the pathogenesis of Churg-Strauss syndrome.  Clin Exp Rheumatol. 2003;  21(6 suppl 32) S69-S77
• 25 Kiene M, Csernok E, Muller A et al.. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome.  Arthritis Rheum. 2001;  44 469-473
• 26 Bockenstedt P L, Santinga J T, Bolling S F. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome.  Am J Hematol. 1994;  45 248-251
• 27 Mohr C, Schutte B, Hildebrand A, Luger T A, Kolde G. Eosinophilic pustular folliculitis: successful treatment with interferon-alpha.  Dermatology. 1995;  191 257-259
• 28 Husak R, Goerdt S, Orfanos C E. Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection.  N Engl J Med. 1997;  337 641-642
• 29 Aldebert D, Lamkhioued B, Desaint C et al.. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators.  Blood. 1996;  87 2354-2360
• 30 Tatsis E, Schnabel A, Gross W L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.  Ann Intern Med. 1998;  129 370-374
• 31 Lesens O, Hansmann Y, Nerson J et al.. Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy.  Eur J Intern Med. 2002;  13 458
• 32 Kroegel C, Mock B, Reissig A. Interferons and their application in lung diseases.  Chest. 2003;  124 2406-2407
• 33 Termeer C C, Simon J C, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement.  Arch Dermatol. 2001;  137 136-138
• 34 Hellmich B, Gross W L. Recent progress in the pharmacotherapy of Churg-Strauss syndrome.  Expert Opin Pharmacother. 2004;  5 25-35
• 35 Arbach O, Gross W L, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade.  Immunobiology. 2002;  206 496-501
• 36 Weyand C M, Goronzy J J. Medium- and large-vessel vasculitis.  N Engl J Med. 2003;  349 160-169
• 37 Weyand C M, Goronzy J J. Giant-cell arteritis and polymyalgia rheumatica.  Ann Intern Med. 2003;  139 505-515
• 38 Brack A, Geisler A, Martinez-Taboada V M et al.. Giant cell vasculitis is a T cell-dependent disease.  Mol Med. 1997;  3 530-543
• 39 Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.  Arthritis Rheum. 2001;  44 2933-2935
• 40 Andonopoulos A P, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.  Ann Rheum Dis. 2003;  62 1116
• 41 Airo P, Antonioli C M, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.  Rheumatology (Oxford). 2002;  41 347-349
• 42 Tan A L, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept.  Ann Rheum Dis. 2003;  62 373-374
• 43 Agnello V, Romain P L. Mixed cryoglobulinemia secondary to hepatitis C virus infection.  Rheum Dis Clin North Am. 1996;  22 1-21
• 44 Sneller M C, Fauci A S. Pathogenesis of vasculitis syndromes.  Med Clin North Am. 1997;  81 221-242
• 45 Dispenzieri A, Gorevic P D. Cryoglobulinemia.  Hematol Oncol Clin North Am. 1999;  13 1315-1349
• 46 Lamprecht P, Gause A, Gross W L. Cryoglobulinemic vasculitis.  Arthritis Rheum. 1999;  42 2507-2516
• 47 Vassilopoulos D, Calabrese L H. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies.  Arthritis Rheum. 2002;  46 585-597
• 48 Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon.  Am J Med. 1987;  83 726-730
• 49 Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia.  Blood. 1991;  78 3142-3147
• 50 Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia.  Clin Exp Rheumatol. 1995;  13(suppl 13) S175-S180
• 51 Cresta P, Musset L, Cacoub P et al.. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.  Gut. 1999;  45 122-128
• 52 Mazzaro C, Lacchin T, Moretti M et al.. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia.  Clin Exp Rheumatol. 1995;  13(suppl 13) S181-S185
• 53 Casato M, Agnello V, Pucillo L P et al.. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.  Blood. 1997;  90 3865-3873
• 54 Pellicano R, Marietti G, Leone N et al.. Mixed cryoglobulinaemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon?.  J Gastroenterol Hepatol. 1999;  14 1108-1111
• 55 Cohen P, Nguyen Q T, Deny P et al.. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies: a prospective study on 20 patients.  Ann Med Interne (Paris). 1996;  147 81-86
• 56 Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia.  J Hepatol. 1997;  27 63-71
• 57 Calleja J L, Albillos A, Moreno-Otero R et al.. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.  Aliment Pharmacol Ther. 1999;  13 1179-1186
• 58 Misiani R, Bellavita P, Fenili D et al.. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Engl J Med. 1994;  330 751-756
• 59 Ferri C, Marzo E, Longombardo G et al.. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial.  Blood. 1993;  81 1132-1136
• 60 Dammacco F, Sansonno D, Han J H et al.. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.  Blood. 1994;  84 3336-3343
• 61 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet. 1998;  352 1426-1432
• 62 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492
• 63 Cacoub P, Lidove O, Maisonobe T et al.. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.  Arthritis Rheum. 2002;  46 3317-3326
• 64 Zuckerman E, Keren D, Slobodin G et al.. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.  J Rheumatol. 2000;  27 2172-2178
• 65 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
• 66 Hadziyannis S J, Sette H, Morgan T R et al.. Peginterferon-alpha2a and ribavirin combination therapy inchronic hepatitis C: a randomized study of treatment duration and ribavirin dose.  Ann Intern Med. 2004;  140 346-355
• 67 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 68 Sansonno D, De Re V, Lauletta G et al.. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.  Blood. 2003;  101 3818-3826
• 69 Zaja F, De Vita S, Mazzaro C et al.. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.  Blood. 2003;  101 3827-3834
• 70 Arzoo K, Sadeghi S, Liebman H A. Treatment of refractory antibody-mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).  Ann Rheum Dis. 2002;  61 922-924
• 71 Lamprecht P, Lerin-Lozano C, Merz H et al.. Rituximab induces remission in refractory HCV-associated cryoglobulinaemic vasculitis.  Ann Rheum Dis. 2003;  62 1230-1233
• 72 Gocke D J, Hsu K, Morgan C et al.. Association between polyarteritis and Australia antigen.  Lancet. 1970;  2 1149-1153
• 73 Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN).  Vox Sang. 1970;  19 410-411
• 74 Guillevin L, Lhote F, Sauvaget F et al.. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.  Ann Rheum Dis. 1994;  53 334-337
• 75 Nakamura H, Shimizu T, Ohshiro S et al.. An adult patient with acute hepatitis type B which was protracted and complicated by polyarteritis nodosa: a case report.  Hepatol Res. 2002;  24 439-444
• 76 Duzova A, Bakkaloglu A, Yuce A, Ozen S, Kocak N. Successful treatment of polyarteritis nodosa with interferon alpha in a nine-month-old girl.  Eur J Pediatr. 2001;  160 519-520
• 77 Deleaval P, Stadler P, Descombes E et al.. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids.  Clin Rheumatol. 2001;  20 290-292
• 78 Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus-associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon, and lamivudine.  J Hepatol. 2000;  33 677-683
• 79 Wicki J, Olivieri J, Pizzolato G et al.. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha.  Rheumatology (Oxford). 1999;  38 183-185
• 80 Molloy P J, Friedlander L, Van Thiel D H, Kania R J. Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa.  Hepatogastroenterology. 1999;  46 2529-2531
• 81 Avsar E, Savas B, Tozun N, Ulusoy N B, Kalayci C. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy.  J Hepatol. 1998;  28 525-526
• 82 Kruger M, Boker K H, Zeidler H, Manns M P. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.  J Hepatol. 1997;  26 935-939
• 83 Sonntag K C, Schwarz-Eywill M, Hunstein W. Is interferon alpha a therapy for hepatitis B-associated polyarteritis nodosa?.  Br J Rheumatol. 1995;  34 486-487
• 84 Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone.  J Clin Gastroenterol. 1995;  20 263-265
• 85 Darras-Joly C, Lortholary O, Cohen P, Brauner M, Guillevin L. Regressing microaneurysms in 5 cases of hepatitis B virus-related polyarteritis nodosa.  J Rheumatol. 1995;  22 876-880
• 86 Mouthon L, Deblois P, Sauvaget F et al.. Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy.  Am J Nephrol. 1995;  15 266-269
• 87 Frassanito M A, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12.  Arthritis Rheum. 1999;  42 1967-1974
• 88 Turan B, Gallati H, Erdi H et al.. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity.  J Rheumatol. 1997;  24 128-132
• 89 Sfikakis P P. Behçet's disease: a new target for anti-tumour necrosis factor treatment.  Ann Rheum Dis. 2002;  61(suppl 2) ii51-ii53
• 90 Sfikakis P P, Theodossiadis P G, Katsiari C G, Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.  Lancet. 2001;  358 295-296
• 91 Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease.  Lancet. 2001;  358 1644
• 92 Triolo G, Vadala M, Accardo-Palumbo A et al.. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.  Ann Rheum Dis. 2002;  61 560-561
• 93 Morris D S, Gavin M P, Sturrock R D. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.  Adv Exp Med Biol. 2003;  528 557-559
• 94 Goossens P H, Verburg R J, Breedveld F C. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.  Ann Rheum Dis. 2001;  60 637
• 95 Robertson L P, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.  Rheumatology (Oxford). 2001;  40 473-474
• 96 Saulsbury F T, Mann J A. Treatment with infliximab for a child with Behçet's disease.  Arthritis Rheum. 2003;  49 599-600
• 97 Gulli S, Arrigo C, Bocchino L et al.. Remission of Behçet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.  BMC Musculoskelet Disord. 2003;  4 19
• 98 Behrens F, Zollner T, Moeller B et al.. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.  Adv Exp Med Biol. 2003;  528 561-562
• 99 Estrach C, Mpofu S, Moots R J. Behçet's syndrome: response to infliximab after failure of etanercept.  Rheumatology (Oxford). 2002;  41 1213-1214
• 100 Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment.  Ann Rheum Dis. 2002;  61 283-284
• 101 Mussack T, Landauer N, Ladurner R et al.. Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab.  Am J Gastroenterol. 2003;  98 703-704
• 102 Kram M T, May L D, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.  Dis Colon Rectum. 2003;  46 118-121
• 103 Hassard P V, Binder S W, Nelson V, Vasiliauskas E A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.  Gastroenterology. 2001;  120 995-999
• 104 Travis S P, Czajkowski M, McGovern D P, Watson R G, Bell A L. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.  Gut. 2001;  49 725-728
• 105 Licata G, Pinto A, Tuttolomondo A et al.. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.  Ann Rheum Dis. 2003;  62 280-281
• 106 Alpsoy E, Kodelja V, Goerdt S, Orfanos C E, Zouboulis Ch C. Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro.  Dermatology. 2003;  206 225-232
• 107 Kotter I, Gunaydin I, Treusch M et al.. The use of interferon-alpha in Behçet's disease: review of the literature and possible mechanisms of action.  Adv Exp Med Biol. 2003;  528 503-509
• 108 Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease.  Clin Exp Immunol. 1990;  79 28-34
• 109 Krause L, Turnbull J R, Torun N et al.. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.  Adv Exp Med Biol. 2003;  528 511-519
• 110 Krause L, Hoffmann F, Zouboulis C C, Foerster M H. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report.  Graefes Arch Clin Exp Ophthalmol. 2003;  241 871-874
• 111 Deuter C M, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment.  Adv Exp Med Biol. 2003;  528 525-528
• 112 Strohal R, Tschachler E, Breyer S et al.. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen.  Br J Haematol. 1998;  103 788-790
• 113 O'Duffy J D, Calamia K, Cohen S et al.. Interferon-alpha treatment of Behçet's disease.  J Rheumatol. 1998;  25 1938-1944
• 114 Kotter I, Eckstein A K, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.  Br J Ophthalmol. 1998;  82 488-494
• 115 Hamuryudan V, Ozyazgan Y, Fresko Y et al.. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.  Isr Med Assoc J. 2002;  4(11 Suppl) 928-930
• 116 Calguneri M, Ozturk M A, Ertenli I et al.. Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study.  Ann Rheum Dis. 2003;  62 492-493
• 117 Nichols J C, Ince A, Akduman L, Mann E S. Interferon-alpha 2a treatment of neuro-Behçet disease.  J Neuroophthalmol. 2001;  21 109-111
• 118 Wechsler B, Bodaghi B, Huong D L et al.. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.  Ocul Immunol Inflamm. 2000;  8 293-301
• 119 Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease.  Br J Ophthalmol. 2000;  84 1437-1438
• 120 Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behçet's disease.  Dermatology. 2000;  201 40-43
• 121 Kotter I, Aepinus C, Graepler F et al.. HHV8-associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha.  Ann Rheum Dis. 2001;  60 83-86
• 122 Aoki T, Tanaka T, Akifuji Y et al.. Beneficial effects of interferon-alpha in a case with Behçet's disease.  Intern Med. 2000;  39 667-669
• 123 Kosar A, Haznedaroglu S, Karaaslan Y et al.. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease.  Rheumatol Int. 1999;  19 11-14
• 124 Georgiou S, Monastirli A, Pasmatzi E et al.. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.  J Intern Med. 1998;  243 367-372
• 125 Pivetti-Pezzi P, Accorinti M, Pirraglia M P, Priori R, Valesini G. Interferon alpha for ocular Behçet's disease.  Acta Ophthalmol Scand. 1997;  75 720-722
• 126 Kotter I, Durk H, Eckstein A et al.. Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma.  Clin Exp Rheumatol. 1996;  14 313-315
• 127 Azizlerli G, Sarica R, Kose A et al.. Interferon alfa-2a in the treatment of Behçet's disease.  Dermatology. 1996;  192 239-241
• 128 Munke H, Stockmann F, Ramadori G. Possible association between Behçet's syndrome and chronic hepatitis C virus infection.  N Engl J Med. 1995;  332 400-401
• 129 Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease.  J Am Acad Dermatol. 1994;  31 617-619
• 130 Feron E J, Rothova A, van Hagen P M, Baarsma G S, Suttorp-Schulten M S. Interferon-alpha 2b for refractory ocular Behçet's disease.  Lancet. 1994;  343 1428
• 131 Hamuryudan V, Moral F, Yurdakul S et al.. Systemic interferon alpha 2b treatment in Behçet's syndrome.  J Rheumatol. 1994;  21 1098-1100
• 132 Durand J M, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-alpha 2b in Behçet's disease.  Arthritis Rheum. 1993;  36 1025-1026
• 133 Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.  Arch Dermatol Res. 1986;  278 335-336
• 134 Grimbacher B, Wenger B, Deibert P et al.. Loss of vision and diarrhoea.  Lancet. 1997;  350 1818
• 135 Durusoy C, Alpsoy E, Yilmaz E. Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A.  J Dermatol. 1999;  26 225-228
• 136 Zouboulis C C, Orfanos C E. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.  Arch Dermatol. 1998;  134 1010-1016
• 137 Alpsoy E, Durusoy C, Yilmaz E et al.. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.  Arch Dermatol. 2002;  138 467-471
• 138 Kotter I, Zierhut M, Eckstein A K et al.. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis.  Br J Ophthalmol. 2003;  87 423-431
• 139 Lockwood C M, Hale G, Waldman H, Jayne D R. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.  Rheumatology (Oxford). 2003;  42 1539-1544